A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-033 Tablets in Patients with Advanced Solid Tumors.
Sichuan, Chengdu 610041, China
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
Patients with histologically confirmed locally advanced unresectable or metastatic solid tumors;
At least one measurable lesion according to RECIST 1.1.
Pregnant and lactating women, or women planning to become pregnant during the study through at least 6 months after the last dose of study drug.
Patients with unstable primary central nervous system (CNS) tumors or CNS metastases.
Patients who have active or history of interstitial lung disease or noninfectious pneumonia.
Patients with QTc > 450 ms in males and > 470 ms in females on ECG at screening, or other clinically significant abnormalities in the ECG at the discretion of the investigator.
Patient with the Medication history and surgical history as stated in the protocol
Those who are unsuitable for blood collection or contraindicated for blood collection.
Other conditions considered unsuitable for participation in this trial at the discretion of the investigator.
Study Contact Info
Contact Listings Owner Form
A Study of ICP-033 in Patients With Advanced Solid Tumors 0 reviewsWrite Your Review
There are no reviews yet.